Sweden's Meds Apotek posts positive Q2 EPS as sales rise

Meds Apotek AB

21/07/2026 06:39

    

    Overview
  
Sweden online pharmacy's Q2 net sales rose 18% yr/yr to SEK 304 mln
Adjusted EPS for Q2 turned positive to SEK 0.31 from a loss last year
Company cites scalable business model and logistics centre launch for continued growth

    

    Outlook
  
Company prioritizes continued profitable growth in second half of 2026
Company expects successful establishment and start-up of Eskilstuna logistics centre
Company says operational risk reduced by using existing machinery and processes

    

    Result Drivers
  
SCALABLE BUSINESS MODEL - CEO said EBIT growth and higher sales demonstrate the scalability of the company's business model
LOGISTICS CENTRE EXPANSION - Co prioritizing the establishment and start-up of the Eskilstuna logistics centre for continued growth

    
Company press release: ID:nMFN7fwNqG

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Revenue
 
SEK 304 mln
 
Q2 Adjusted EPS
 
SEK 0.31
 
Q2 Adjusted Free Cash Flow
 
-SEK 300,000
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy."
Wall Street's median 12-month price target for Meds Apotek AB is SEK47.50, about 123% above its July 20 closing price of SEK21.30
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 14 three months ago

    

    Reuters Recommended Reads
  
July 21 - Sweden's MedCap Q2 net sales rise 16% on organic growth and acquisitions
July 20 - Sweden's Devyser Diagnostics Q2 sales fall on distributor inventory adjustment
July 21 - Switzerland's Novartis beats Q2 sales estimates on strong sales across priority brands

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)